Treating Nightmares in Posttraumatic Stress Disorder With Dronabinol
Status:
Recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
This randomized controlled exploratory phase II trial will test the hypothesis that oral
dronabinol improves nightmares (primary outcome) and other PTSD symptoms (secondary outcomes)
to a greater extent than placebo over a ten week intervention phase in a parallel group
design.